Bill with covered CPT codes and confirm plan PA rules

When coverage is available, CPT 90901, 90912, and 90913 are considered medically necessary when the policy criteria are met; providers must refer to the customer's benefit plan document for prior authorization requirements and use the appropriate codes when billing.

• CPT 90901 — Biofeedback training by any modality.
• CPT 90912 — Biofeedback training, perineal muscles, anorectal or urethral sphincter; initial 15 minutes one-on-one contact.
• CPT 90913 — Biofeedback training, perineal muscles, anorectal or urethral sphincter; each additional 15 minutes one-on-one contact.

Provide documentation of clinical setting and qualified provider

Biofeedback must be performed in a clinical setting with the continuous one-on-one face-to-face presence of the physician or a qualified non-physician practitioner (e.g., PT, OT, NP, PA, CNS); if the payer requires prior authorization for outpatient therapy, evidence of the clinical setting and qualified provider may be requested.

• Continuous presence = one-on-one face-to-face involvement during training.
• Qualified non-physician practitioners include physical and occupational therapists, nurse practitioners, physician assistants, and clinical nurse specialists.

No specific prior authorization requirements in policy text

The policy text does not specify a uniform prior authorization process; providers must refer to the customer's benefit plan document for any plan-specific prior authorization requirements.

• No specific prior authorization rules for biofeedback are stated in these sections of the policy.

Confirm anorectal diagnosis and prior conservative management for PA

For anorectal (defecatory) biofeedback, prior authorization, when required by the plan, should confirm the diagnosis of dyssynergic defecation or refractory anorectal disorder and that appropriate conservative treatments have failed or were not tolerated.

• Document diagnostic confirmation (e.g., anorectal physiologic testing or clinical assessment showing dyssynergic pattern).
• Document failure/intolerance/contraindication of conservative therapies (laxatives, diet/fiber modifications, behavioral measures) unless first-line biofeedback is indicated per guidance.

Evidence variability may prompt case-by-case PA review

Although some sections cite references, they do not state explicit prior authorization rules; because evidence is variable, payers may require case-by-case review where services are considered investigational or adjunctive.

• No explicit prior authorization rules are provided in these reference-only sections.
• Variability in evidence quality may prompt prior authorization or individualized review.

Require rationale and documentation for EEG/neurofeedback PA

For EEG neurofeedback (neurofeedback), prior authorization should require a clear clinical rationale, targeted symptoms and proposed protocol, and evidence that conventional therapies were tried, because randomized trial evidence and systematic reviews are heterogeneous and insufficient to broadly support routine coverage.

• Provide rationale, targeted symptoms, session number/frequency, and supporting literature.
• Document prior trials of conventional therapies and why neurofeedback is being considered.

Justify proprietary systems and home devices in PA requests

Prior authorization may be required to justify use of proprietary systems or home biofeedback devices (e.g., InTandem or unsupervised home devices) because published peer‑reviewed evidence does not consistently show additional benefit over standard clinic-based rehabilitation.

• Document why a proprietary system or home device is necessary versus supervised clinic-based biofeedback.
• Provide evidence of expected benefit and plan for monitoring outcomes if home/proprietary use is requested.

Cite CMS NCD and decision memo in PA justification

References cited in the policy include the CMS National Coverage Determination for Biofeedback Therapy (NCD 30.1) and a CMS decision memo on home biofeedback for urinary incontinence; these are relevant sources payers may consider when reviewing prior authorization requests.

• CMS decision memo (2002) on home biofeedback for urinary incontinence.
• CMS NCD 30.1 for Biofeedback Therapy (CPT 93010 referenced).

References only — no PA criteria stated here

This section contains references only and does not specify prior authorization requirements; providers should rely on the member's benefit plan for PA rules.

• References may support medical necessity arguments but do not replace plan PA rules.

Document conservative therapy failure prior to biofeedback

Before authorizing biofeedback for covered indications, documentation should show failure, intolerance, or contraindication of appropriate conservative therapies (e.g., laxatives, dietary/fiber modification, behavioral measures) except where guidance supports first-line biofeedback for selected pelvic floor dyssynergia.

• For anorectal dyssynergia, document prior conservative measures and their lack of efficacy.
• For fecal or urinary incontinence, show failure or intolerance of indicated nonpharmacologic treatments when required by the policy.

Require first-line conservative UI treatments before biofeedback

For urinary incontinence, first-line conservative treatments (lifestyle modification and pelvic floor muscle training) are expected before adjunctive biofeedback, unless biofeedback is being used to assist patients who cannot actively contract pelvic floor muscles.

• Document attempts at lifestyle modification and supervised PFMT per standard protocols.
• If biofeedback is used because the patient cannot actively contract pelvic floor muscles, document that limitation.

Position biofeedback as second-line/adjunctive therapy

Multiple guidance documents recommend biofeedback as a second-line or adjunctive therapy after initial conservative measures for fecal incontinence and related anorectal disorders; providers should document prior conservative care before requesting authorization.

• NICE and ASCRS recommend against routine first-line use; consider biofeedback after conservative management failure.
• Document prior use of antidiarrheals, fiber, behavioral training, or other conservative measures.

Require stepwise sequence for defecatory disorder therapies

For defecatory disorders, biofeedback is recommended after failure of conservative management and before more invasive procedures (e.g., subtotal colectomy); prior authorization should document conservative therapy attempts and diagnostic confirmation of dyssynergic defecation.

• Document objective or clinical confirmation of dyssynergic pattern (e.g., anorectal physiologic testing).
• Show that conservative measures failed, were not tolerated, or are contraindicated before authorizing biofeedback.

Prefer guideline-recommended nonpharmacologic first-line therapies

Guidance emphasizes nonpharmacologic first-line treatments (e.g., PFMT, CBT, exercise) for many chronic conditions; biofeedback should generally follow guideline‑recommended noninvasive therapies rather than precede them.

• Follow condition-specific guideline hierarchies before considering biofeedback.
• Document prior use of recommended nonpharmacologic therapies when applicable.

Follow guideline hierarchy before specialized biofeedback

For chronic conditions like TMD and vulvodynia, follow guideline-recommended hierarchies: prioritize strongly recommended noninvasive therapies (e.g., CBT ± biofeedback for TMD) and conservative measures before specialized biofeedback.

• Document prior trials of recommended noninvasive treatments and rationale for adding biofeedback.

Require supervised PFMT before authorizing home biofeedback devices

Consider requiring supervised pelvic floor muscle training (PFMT) and clinic-based biofeedback before authorizing standalone home biofeedback devices for urinary incontinence, given stronger evidence for supervised approaches.

• Document supervised PFMT attempts and outcomes prior to approving home-device use.
• If authorizing a home device, require a plan for supervised integration and outcome monitoring.

No extra step therapy rules in reference citations

The reference citations reviewed do not describe additional step therapy requirements beyond those summarized in the policy; payers may adopt plan‑specific step therapy protocols.

• No further step therapy rules are specified in these reference listings.

References only — no step therapy rules here

These reference chunks do not contain explicit step therapy rules; rely on the policy and the member's benefit plan for any required stepwise treatment sequence.

• References are provided for clinical context but do not prescribe step therapy algorithms.

Include required elements in the written treatment plan

A written treatment plan is required and must include the specific diagnosis/conditions to be treated, long- and short-term goals, measurable objectives, and the time frame and frequency of treatment.

• Include diagnosis, goals, measurable objectives, time frame, and frequency in the plan.
• Use the treatment plan to document expected milestones and rationale for continuing therapy.

Confirm patient cognitive status and motivation in documentation

Document that the patient is cognitively intact and willing/motivated to learn and practice the tasks required by biofeedback, as lack of capacity or motivation may affect eligibility and outcomes.

• Record cognitive status and evidence of patient engagement or barriers to participation.

Document supervised, face-to-face delivery and practitioner involvement

Documentation should confirm one-on-one face-to-face involvement by a physician or qualified non‑physician practitioner during supervised biofeedback sessions.

• Note the practitioner type and that continuous face-to-face supervision occurred during sessions.
• Specify setting (clinic vs home) and whether supervised or unsupervised delivery was used.

Document objective outcome measures and follow-up

Use validated outcome measures described in trials (e.g., UDI-6 symptom scores, uroflowmetry parameters Qmax/Qave, post-void residual, 24-hour leakage episodes, pad tests, bladder diaries, standardized functional scores) to document baseline status and response to therapy.

• Record baseline and follow-up UDI-6, uroflowmetry, PVR, leakage frequency, and quality-of-life measures where applicable.
• Attach objective test results when available to support continued therapy authorization.

Document clinical indication and prior conservative therapy for anorectal biofeedback

When authorizing biofeedback for defecatory disorders, document the clinical indication (dyssynergic defecation or refractory defecatory disorder) and prior failure of conservative management consistent with AGA/ASCRS/ANMS recommendations.

• Include diagnostic testing or clinical assessment confirming dyssynergic defecation.
• List prior conservative treatments tried and their outcomes.

Document condition‑specific outcome measures and follow-up

Document trial outcomes using standardized measures appropriate to the condition (examples used in trials include ROM, strength measures, American Shoulder and Elbow score, Numeric Pain Rating Scale, and Global Rating of Change) and the duration of follow‑up.

• Provide baseline and post-treatment scores and specify timing of assessments.
• Use condition‑specific validated instruments when available.

Provide detailed documentation for mixed/limited-evidence indications

For indications with mixed or limited evidence (e.g., recurrent UTI with dysfunctional voiding, vulvodynia), documentation should include diagnosis, prior conservative treatments tried, the specific biofeedback modality and treatment plan, and outcomes monitoring to justify continued therapy.

• Specify modality (EMG, uroflowmetry, HRV, EEG), session frequency, and planned duration.
• Report objective outcome data and adherence to therapy.

Record delivery setting, protocol, adherence and outcomes

Documentation should include the setting of biofeedback delivery (clinical supervised vs home), the protocol used, adherence data, and outcome measures because supervised delivery is more consistently supported than unsupervised/home-device use.

• If home device use is claimed, document supervised components, adherence monitoring, and objective outcomes.
• Note device make/model when relevant and any training provided to the patient.

References can support documentation but do not replace plan requirements

These reference chunks provide citations (including CMS decision memos and NCDs) that may support documentation or PA requests, but they do not themselves state an explicit documentation checklist.

• Use referenced CMS guidance and systematic reviews to support medical necessity arguments when applicable.

Claims without covered codes will be denied

Claims for services submitted without covered codes under this policy will be denied as not covered; ensure billed procedure codes match those listed as covered when criteria are met.

• Verify use of CPT 90901, 90912, 90913 when billing for covered biofeedback services.
• Do not bill covered services under non‑covered CPT/HCPCS codes listed as investigational without prior plan approval.

Denial risk if continuous face-to-face supervision is not documented

Absence of continuous one-on-one face-to-face clinician presence during biofeedback sessions may trigger claim denial; document supervised, in-person involvement by the treating clinician or qualified practitioner.

• Specify that continuous presence occurred and who provided the face-to-face supervision.
• If sessions were unsupervised or home-based, expect closer scrutiny and potential denial without supporting documentation.

No administrative denial triggers specified in evidence summaries

These clinical evidence summaries do not list administrative denial triggers or specific authorization procedures; however, plan or payer-specific authorization processes may still apply.

• No explicit administrative denial triggers are provided in these clinical evidence summaries.

High denial risk for pediatric idiopathic constipation

Use of biofeedback for childhood idiopathic constipation is not supported by the evidence and guideline statements recommend against routine use; claims for biofeedback in pediatric idiopathic constipation may be denied.

• NICE and NASPGHAN/ESPGHAN guidance recommend against routine use in children and young people.
• Document any exceptional clinical rationale if seeking authorization for pediatric cases.

Evidence limitations may prompt denial or investigational classification

Evidentiary limitations—small trials, heterogeneity, short follow-up, and low certainty—are repeatedly noted and may prompt denial or classification of a requested service as investigational for many indications lacking robust data.

• Provide higher‑quality supporting evidence and objective outcomes when requesting coverage for indications with limited evidence.
• Be prepared for case-by-case review for indications with mixed or low-certainty data.

Denial risk when evidence shows no added benefit versus standard therapy

When evidence shows no additional benefit of biofeedback over established therapies (e.g., EMG biofeedback vs exercise for patellofemoral pain or adding biofeedback to conventional therapy in children), denials may occur unless individualized benefit is documented.

• Document individualized clinical rationale and objective outcome measures to justify therapy where pooled analyses show no added benefit.
• Avoid routine authorization for indications where high-quality evidence demonstrates no incremental benefit.

Home device use may be denied without supervised program and outcomes

Home biofeedback devices lack consistent evidence of effectiveness in peer-reviewed literature; use of home devices may trigger denial or require additional documentation of supervised integration and objective outcomes.

• If requesting coverage for a home device, include evidence of supervised training, adherence monitoring, and measurable outcomes.
• Cite recent trials showing benefit only when home devices are combined with supervised PFMT, if applicable.

InTandem claims may be denied without supportive comparative evidence

The InTandem Neurorehabilitation System is not supported by current peer‑reviewed evidence as superior to standard clinic or home rehabilitation; claims for InTandem may be denied without robust comparative evidence.

• Provide comparative evidence if requesting coverage for InTandem; absence of such evidence may lead to denial.

References do not provide explicit authorization/denial triggers

These reference listings do not state explicit authorization or denial triggers; payers should rely on the policy criteria and the member's benefit document to determine coverage and authorization decisions.

• References support clinical context but do not replace plan-specific coverage or PA rules.

Reference pages — no direct authorization or documentation criteria

These reference pages contain only citations and do not specify authorization or documentation requirements directly; providers must follow the policy and plan rules when submitting requests.

• Use the referenced literature to support medical necessity arguments but include required documentation per the policy and benefit plan.